The first clinically validated biomarker platform capable of predicting Type 2 Diabetes years before diagnosis.
Science Behind LDcoder
THE DISCOVERY
Elevated circulating follistatin predicts future Type 2 Diabetes years before diagnosis.
Researchers revealed that elevated levels of the biomarker follistatin were strongly associated with future development of Type 2 Diabetes, appearing up to 20 years before clinical symptoms emerged.
The discovery is based on extensive longitudinal studies involving more than 8,000 individuals followed for up to 20 years across multiple international cohorts.
This scientific foundation powers LDcoder, enabling earlier identification of at-risk individuals during a critical prevention window.
WHY FOLLISTATIN?
Follistatin is a circulating protein involved in metabolic regulation, insulin sensitivity, and inflammatory pathways. Multiple independent studies have demonstrated that elevated follistatin levels are associated with increased future risk of Type 2 Diabetes. LDcoder combines precise biomarker quantification with advanced machine learning to identify risk patterns years before conventional diagnosis is possible.
PEER-REVIEWED EVIDENCE
Elevated circulating follistatin associates with increased future risk of Type 2 Diabetes
Published: 2021
International collaborative study
Scientific foundation of the LDcoder platform
Early identification creates opportunities for intervention before disease onset.
LDcoder helps identify individuals during the years when lifestyle, monitoring, and preventive care can have the greatest impact.